{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:10:18Z","timestamp":1756375818066,"version":"3.44.0"},"reference-count":7,"publisher":"SMC Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"Transplant-associated thrombotic microangiopathy (TA-TMA) can occur after solid organ transplantation. It results in thrombocytopenia, haemolytic anaemia and microvascular occlusion. TA-TMA is not fully understood and treatment has not been clearly established. However, there is increasing evidence to suggest an immune-complement mediated component to its development. Eculizumab is a monoclonal antibody that inhibits the cleavage of C5 into pro-inflammatory, prothrombotic terminal complement elements and has been utilized in the treatment of atypical haemolytic uremic syndrome. We report a case of TA-TMA successfully treated with eculizumab and romiplostim. This case adds to the evidence that TA-TMA is triggered by complement dysregulation and suggests possible interventions for refractory cases.<\/jats:p>","DOI":"10.12890\/2021_002294","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T09:52:37Z","timestamp":1621936357000},"source":"Crossref","is-referenced-by-count":1,"title":["Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim"],"prefix":"10.12890","volume":"8","author":[{"given":"Muhammad","family":"Awidi","sequence":"additional","affiliation":[{"name":"Lahey Hospital and Medical Center, Burlington, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenu","family":"Jain","sequence":"additional","affiliation":[{"name":"Lahey Hospital and Medical Center, Burlington, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Baur","sequence":"additional","affiliation":[{"name":"Lahey Hospital and Medical Center, Burlington, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10397","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"10.12890\/2021_002294_ref1","doi-asserted-by":"crossref","unstructured":"
  • Nwaba A, MacQuillan G, Adams LA, Garas G, Delriviere L, Augustson B, et al. Tacrolimus-induced thrombotic microangiopathy in orthotopic liver transplant patients: case series of four patients. Intern Med J<\/em> 2013;43<\/strong>(3):328\u2013333.<\/li>","DOI":"10.1111\/imj.12048"},{"key":"10.12890\/2021_002294_ref2","unstructured":"
  • Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol<\/em> 2014;12<\/strong>(9):565\u2013573.<\/li>"},{"key":"10.12890\/2021_002294_ref3","doi-asserted-by":"crossref","unstructured":"
  • Tamura S, Sugawara Y, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, et al. Thrombotic microangiopathy in living-donor liver transplantation. Transplantation<\/em> 2005;80<\/strong>(2):169\u2013175.<\/li>","DOI":"10.1097\/01.TP.0000165048.00487.8E"},{"key":"10.12890\/2021_002294_ref4","doi-asserted-by":"crossref","unstructured":"
  • Wijnsma KL, Ter Heine R, Moes D, Langemeijer S, Schols SEM, Volokhina EB, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet<\/em> 2019;58<\/strong>(7):859\u2013874.<\/li>","DOI":"10.1007\/s40262-019-00742-8"},{"key":"10.12890\/2021_002294_ref5","doi-asserted-by":"crossref","unstructured":"
  • Okano M, Sakata N, Ueda S, Takemura T. Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia. Bone Marrow Transplant<\/em> 2014;49<\/strong>(8):1116\u20131118.<\/li>","DOI":"10.1038\/bmt.2014.97"},{"key":"10.12890\/2021_002294_ref6","doi-asserted-by":"crossref","unstructured":"
  • Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol<\/em> 2013;161<\/strong>(2):279\u2013280.<\/li>","DOI":"10.1111\/bjh.12202"},{"key":"10.12890\/2021_002294_ref7","doi-asserted-by":"crossref","unstructured":"
  • Dhakal P, Giri S, Pathak R, Bhatt VR. Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost<\/em> 2017;23<\/strong>(2):175\u2013180.<\/li>","DOI":"10.1177\/1076029615599439"}],"container-title":["European Journal of Case Reports in Internal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/2294\/2552","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/2294\/2553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/2294\/2553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:43:15Z","timestamp":1756374195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/2294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":7,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.12890\/2021_002294","relation":{"has-manifestation":[{"id-type":"other","id":"1-67-2294-g2552","asserted-by":"subject"},{"id-type":"other","id":"1-67-2294-g2553","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-67","asserted-by":"subject"}]},"ISSN":["2284-2594"],"issn-type":[{"type":"electronic","value":"2284-2594"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"article-number":"19"}}